<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04657952</url>
  </required_header>
  <id_info>
    <org_study_id>34268/11/20</org_study_id>
    <nct_id>NCT04657952</nct_id>
  </id_info>
  <brief_title>Sphenopalatine Ganglion Block for Post-Dural Puncture Headache in Orthopedic Patients</brief_title>
  <official_title>Sphenopalatine Ganglion Block With Adrenaline Additive for Post-Dural Puncture Headache in Orthopedic Patients: A Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess the efficacy, onset and duration of analgesia of&#xD;
      sphenopalatine ganglion bock (SPGB) using lidocaine 4% with adrenaline as a treatment of&#xD;
      postoperative Post dural puncture headache (PDPH) of orthopedic patients after lower limbs&#xD;
      surgeries.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 10, 2020</start_date>
  <completion_date type="Anticipated">May 20, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 10, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of analgesia demonstrated by visual analogue scale (VAS) less than 4 (effective) in the first 48 hours</measure>
    <time_frame>48 hours</time_frame>
    <description>Efficacy of analgesia demonstrated by visual analogue scale (VAS) less than 4 (effective) in the first 48 hours.&#xD;
VAS ranges from 0 to 10; 10 with worse outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Onset of analgesia</measure>
    <time_frame>48 hours</time_frame>
    <description>The onset time till VASâ‰¥ 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of analgesia</measure>
    <time_frame>48 hours</time_frame>
    <description>Duration with VAS&lt; 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>48 hours</time_frame>
    <description>Local anesthetic toxicity, hypertension, postoperative epistaxis, cheek hematoma and hypoesthesia of the palate</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Sphenopalatine Ganglion Block</condition>
  <condition>Adrenaline</condition>
  <condition>Post-Dural Puncture Headache</condition>
  <condition>Orthopedic</condition>
  <condition>Randomized Controlled Study</condition>
  <arm_group>
    <arm_group_label>Standard medical Treatment (paracetamol)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive paracetamol 1 gm every 6 hours daily intravenously for a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sphenopalatine block</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive sphenopalatine block</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sphenopalatine Ganglion Block</intervention_name>
    <description>Sphenopalatine Ganglion Block will be performed by a transnasal approach. Few drops of lidocaine 2% will be instilled into both anterior nares. Then a cotton-tipped applicator soaked in 4% lignocaine &amp; adrenaline (1 to 200000 will be passed through both the nares and the end of the applicator tip will be positioned just superior to the middle turbinate and anterior to the pterygopalatine fossa and sphenopalatine ganglion for 5 min with the patient in the supine position.</description>
    <arm_group_label>Sphenopalatine block</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Medical Treatment</intervention_name>
    <description>Patients will receive paracetamol 1 gm 6 hours daily intravenously for a day. If adequate pain relief will not be achieved, intravenous diclofenac 75 mg twice daily will be added.</description>
    <arm_group_label>Standard medical Treatment (paracetamol)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Admitted to the orthopedic department&#xD;
&#xD;
          -  Complaining of criteria of severe post-dural puncture headache within 7 days following&#xD;
             subarachnoid block used for lower limbs surgeries.&#xD;
&#xD;
          -  American Society of Anesthesiologists (ASA) physical status I and II.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient refusal or uncooperative.&#xD;
&#xD;
          -  Patients with uncontrollable hypertension.&#xD;
&#xD;
          -  Patient with known coagulopathy.&#xD;
&#xD;
          -  Patient with nasal septal deviation, polyp, history of nasal bleeding.&#xD;
&#xD;
          -  Patient with allergy to local anesthetics&#xD;
&#xD;
          -  American Society of Anesthesiologists physical status&gt;2.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 30, 2020</study_first_submitted>
  <study_first_submitted_qc>December 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2020</study_first_posted>
  <last_update_submitted>December 6, 2020</last_update_submitted>
  <last_update_submitted_qc>December 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Hussen Gamal Almawardy</investigator_full_name>
    <investigator_title>Lecturer of Anesthesiology, Surgical Intensive Care and Pain Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ganglion Cysts</mesh_term>
    <mesh_term>Synovial Cyst</mesh_term>
    <mesh_term>Post-Dural Puncture Headache</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data will be available upon reasonable request</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_access_criteria>3 months after completing the study</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

